Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Firmonertinib and Intrathecal Pemetrexed for EGFR+ NSCLC with LM
NCT07092202Phase 4Recruiting
- Start
- Apr 2025
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of furmonertinib in non-small cell lung cancer (NSCLC). Started Apr 2025; status: recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07092202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07092202.